生物信息学研发主管

成都美杰赛尔生物科技有限公司

Chinese cell therapy company founded in 2015 in Chengdu, Sichuan, working on precision cell medicine research and technical services and operating four GMP cell engineering suites and quality control laboratories in premises it owns. Developed what it describes as the world's first GMP grade gene edited T cell product and, with West China Hospital, completed the world's first human clinical trial of gene edited cells, work reported on the front page of Nature. Runs four technology platforms covering genome editing and epigenetic modification, rapid ex vivo expansion, rapid in vitro assessment of cell medicines and non-viral transfection, and raised tens of millions of yuan in a strategic round from a Zhongguancun Capital fund in January 2025.